Tim Jansen - Concepedia

Author

Tim Jansen

Also Known As

A.B. Joosten, Leo, Antoaneta C. Comarniceanu, Jansen, Jansen, T, Jansen, T., Jansen, T.L.Th.A., Jansen, Tim, Jansen, Tim L, Jansen, Tim L Th A, L Calza

380

Publications

11.2K

Citations

H-Index

104

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center VieCuri Medisch Centrum Medisch Centrum Leeuwarden Medisch Spectrum Twente

About

Tim Jansen is an author at Radboud University Nijmegen specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	1.1K
2	Public Health	4	4	132
3	Engineering	3	3	94
4	Health Sciences	2	2	65
5	Anesthesia	1	1	36

Tim Jansen

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis Weiya Zhang, Michael Doherty, Thomas Bardin, Annals of the Rheumatic Diseases	2011	532
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout Pascal Richette, Michael Doherty, Eliseo Pascual, Annals of the Rheumatic Diseases	2019	404
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra Tania O. Crișan, Maartje C. P. Cleophas, Marije Oosting, Annals of the Rheumatic Diseases	2015	265
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial Viola Klück, Tim Jansen, M. Janssen, The Lancet Rheumatology Anti-inflammatoryGouty ArthritisPharmacologyClinical TrialsPharmacotherapy	2020	257
EULAR recommendations for calcium pyrophosphate deposition. Part II: Management Weiya Zhang, Michael Doherty, Eliseo Pascual, Annals of the Rheumatic Diseases	2011	243
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study Suzanne Arends, Elisabeth Brouwer, E. van der Veer, Arthritis Research & Therapy	2011	223
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout M.K. Reinders, C.J. Haagsma, Tim Jansen, Annals of the Rheumatic Diseases	2008	184
Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout William J. Taylor, Jaap Fransen, Tim Jansen, Arthritis Care & Research	2015	168
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol M.K. Reinders, Eric N. van Roon, Tim Jansen, Annals of the Rheumatic Diseases	2008	159
Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard Alexis Ogdie, William J. Taylor, Tuhina Neogi, Arthritis & Rheumatology	2016	132

Page 1